Key Segmentation:
By Offering
-
Software
-
Services
By Technology
-
Machine Learning
-
Deep Learning
-
Natural Language Processing
-
Computer Vision & Other Technologies
By Application
-
Patient Recruitment & Enrollment
-
Trial Design & Protocol Optimization
-
Data Management & Monitoring
-
Risk-Based Monitoring & Safety Surveillance
By End User
-
Pharmaceutical & Biotechnology Companies
-
Contract Research Organizations (CROs)
-
Academic & Research Institutes
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company's specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The AI in Clinical Trials Market is expected to grow at a CAGR of 26.40% from 2026 to 2035.
The AI in Clinical Trials Market was valued at USD 2.71 Billion in 2025.
The market is driven by rising clinical trial complexity and cost pressure, growing sponsor demand for faster patient recruitment and safety monitoring, and continued advancement of machine learning and generative AI technologies.
The Patient Recruitment & Enrollment segment dominated the AI in Clinical Trials Market in 2025, accounting for approximately 31.60% market share.
The North America region dominated the AI in Clinical Trials Market in 2025 with a market share of 38.60%, driven by the region's mature pharmaceutical R&D ecosystem and early adoption of AI-enabled trial platforms.